Optimization of perioperative treatment strategies for locally advanced esophageal squamous cell carcinoma from the perspective of tumor heterogeneity.
10.3760/cma.j.cn441530-20221126-00494
- Author:
Xiao Zheng KANG
1
;
Rui Xiang ZHANG
1
;
Zhen WANG
1
;
Xian Kai CHEN
1
;
Jian Jun QIN
1
;
Yin LI
1
;
Qi XUE
1
;
Jie HE
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Esophageal Squamous Cell Carcinoma/surgery*;
Carcinoma, Squamous Cell/pathology*;
Esophageal Neoplasms/pathology*;
Combined Modality Therapy;
Immunotherapy
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(4):334-338
- CountryChina
- Language:Chinese
-
Abstract:
Recent advances in multimodality treatment offer excellent opportunities to rethink the paradigm of perioperative management for locally advanced esophageal squamous cell carcinoma. One treatment clearly doesn't fit all in terms of a broad disease spectrum. Individualized treatment of local control of bulky primary tumor burden (advanced T stage) or systemic control of nodal metastatic tumor burden (advanced N stage) is essential. Given that clinically applicable predictive biomarkers are still awaited, therapy selection guided by diverse phenotypes of tumor burden (T vs. N) is promising. Potential challenges regarding the use of immunotherapy may also boost this novel strategy in the future.
